# Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes

- Link: https://www.thailand-business-news.com/pr-news/ascletis-completes-enrollment-in-u-s-phase-ii-study-of-asc30-an-oral-small-molecule-glp-1r-agonist-for-the-treatment-of-diabetes
- Published: 2026-04-27T07:10:00+07:00
- Author: PR Newswire

|   |

_– 13-week U.S. Phase II study is evaluating the efficacy, safety and tolerability
of oral small molecule GLP-1R agonist ASC30, a once-daily tablet, in 100 participants
with diabetes._

_– Topline data from the Phase II study are expected in the third quarter of 2026._

HONG KONG, April 27, 2026 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, "Ascletis")
announces today completion of enrollment in its 13-week U.S. Phase II study ([NCT07321678](https://clinicaltrials.gov/study/NCT07321678?cond=ASC30&viewType=Card&rank=4))
evaluating ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist, for the
treatment of type 2 diabetes mellitus (T2D). T2D is the second indication for ASC30,
following its first indication of obesity. Topline data from the Phase II study 
for the treatment of T2D are expected in the third quarter of 2026.

"ASC30 has potential to be the best-in-class oral small molecule GLP-1 for obesity,
evidenced by its efficacy and tolerability demonstrated by the U.S. Phase II study
in participants with obesity or overweight," said Jinzi Jason Wu, Ph.D., Founder,
Chairman and CEO of Ascletis, "Expanding ASC30’s clinical development into the large
diabetes treatment market is a logical next step that provides us with another chance
to highlight ASC30’s potential best-in-class profile as a once-daily oral treatment
option for patients. We look forward to sharing topline data from the Phase II study
in diabetes participants in the third quarter of 2026."

Dr. Wu added, "Based on the positive clinical results announced in December 2025
from our 13-week U.S. Phase II study of ASC30 in participants with obesity or overweight,
the Company expects to obtain the clearance from the U.S. Food and Drug Administration
and initiate Phase III trials in the U.S. for obesity indication by the end of the
third quarter 2026."

ASC30 was discovered and developed in-house at Ascletis as a first and only investigational
small molecule GLP-1R fully biased agonist that can be dosed once daily orally and
once monthly to once quarterly subcutaneously for the treatment of obesity, diabetes
and other metabolic diseases.

**About the U.S. Phase II Study with ASC30 for the Treatment of Diabetes**

The Phase II study is a 13-week, randomized, double-blind, placebo-controlled and
multi-center study to evaluate the efficacy, safety, and tolerability of ASC30 tablets
in participants with type 2 diabetes mellitus. The primary endpoint of the Phase
II study is the mean change from baseline in HbA1c up to 13 weeks in the treatment
group compared with the placebo group. Secondary endpoints include the mean change
from baseline in fasting blood glucose up to 13 weeks in the treatment group compared
with the placebo group, the mean change from baseline in body weight up to 13 weeks
in the treatment group compared with placebo group, and safety and tolerability.
The Phase II study enrolled 100 participants with type 2 diabetes mellitus at multiple
sites across the U.S. Participants were randomly assigned in a ratio of approximately
2:3:3:2 to 40 mg, 60 mg and 80 mg ASC30 tablets and matching placebo tablets, respectively.
ASC30 was titrated weekly from 1 mg to target doses of 40 mg, 60 mg and 80 mg.

**About Ascletis Pharma Inc.**

Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the 
development and commercialization of potential best-in-class and first-in-class 
therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-
assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (
ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT),
Ascletis has developed multiple drug candidates in-house, including both small molecules
and peptides, such as its lead program, ASC30, a small molecule GLP-1R agonist designed
to be administered once daily orally and once monthly to once quarterly subcutaneously
as a treatment therapy and a maintenance therapy for chronic weight management; 
ASC36, an amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously 
administered GLP-1R/GIPR dual peptide agonist and ASC37, a GLP-1R/GIPR/GCGR triple
peptide agonist, ASC39, a potent and amylin-selective oral small molecule amylin
receptor agonist, and ASC30_39 FDC, a fixed-dose combination (FDC) of ASC30 and 
ASC39, for chronic weight management. Ascletis is listed on the Hong Kong Stock 
Exchange (1672.HK).

For more information, please visit [www.ascletis.com](https://www.ascletis.com/).

Contact:

Peter Vozzo
ICR Healthcare443-231-0505 (U.S.)[Peter.vozzo@icrhealthcare.com](https://www.thailand-business-news.com/pr-news/Peter.vozzo@icrhealthcare.com)

Ascletis Pharma Inc. PR and IR Teams
+86-181-0650-9129 (China)[pr@ascletis.com](https://www.thailand-business-news.com/pr-news/pr@ascletis.com)
[ir@ascletis.com](https://www.thailand-business-news.com/pr-news/ir@ascletis.com)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes ](http://www.prnasia.com/story/archive/4942906_AE42906_0?rand=184833)
